Years ago, a home health nurse came to my house to infuse my medication for von Willebrand disease and hemophilia B. Treatment for my bleeding disorders is often administered intravenously, meaning it’s injected directly into a vein. I’d had surgery a few days before and needed the…

My bleeding disorders, hemophilia B and von Willebrand disease, have significantly affected my family. As I’ve aged, my appreciation for my family has grown tremendously. I’ve come to realize that hemophilia‘s impact isn’t just limited to me; it’s also affected my family in profound ways. True, patients…

Concizumab has been approved as a preventive treatment in Canada for hemophilia B patients ages 12 and older who are positive for factor IX inhibitors and need a routine prophylactic to prevent bleeds or reduce their frequency. This is the first approval for the daily under-the-skin injectable therapy, which…

With an emphasis on patient advocacy, supporters of World Hemophilia Day will participate in a variety of activities on April 17 to heighten awareness of the disease and other bleeding disorders that are thought to affect 1 in 10,000 people globally. The World Federation of Hemophilia (WFH) organizes the…

When my sons were little, there were always mountains of laundry. How could such a tiny human go through so many onesies? There were dozens of little socks to be matched, stains to be treated, and hundreds of pieces of clothing to be folded. It was never-ending. There were weeks…

Historically, hemophilia has been viewed as a disease that affects men and boys, which has led to significant gender bias against women with the disease in research, diagnosis, and treatment. As a result, there’s a lack of awareness and understanding of how hemophilia affects women and…

About one-third of moderate-to-severely affected people with hemophilia perceived declines in their daily functional abilities over a period of three to five years, a Dutch study found. While no strong risk factors for such declines were identified, patients more likely to be affected were those who were obese, had…

Xoma closed a $9.6 million deal to buy from Aptevo Therapeutics the rights to receive a payment stream for sales of Ixinity (trenonacog alfa), an approved medication used to prevent and treat bleeding episodes in people with hemophilia B. Under the terms of the deal, Xoma will…

Significant disparities in access to hemophilia treatment exist around the world. In general, people with hemophilia can live a relatively normal life if their condition is properly managed and they have access to appropriate medical care. However, in developing countries, access to adequate treatment and medical care can…